<DOC>
	<DOCNO>NCT00083239</DOCNO>
	<brief_summary>The purpose study assess antitumor activity safety talabostat patient metastatic melanoma .</brief_summary>
	<brief_title>Study Talabostat Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm melanoma metastatic ( unresectable Stage IV per AJCC 2002 ) Patients measurable disease define least one measurable index lesion clearly define margin ECOG Performance Status 0 , 1 , 2 Expected survival â‰¥12 week Written inform consent More 1 prior chemotherapy biotherapy regimen Stage IV melanoma Radiation therapy &gt; 50 % bone marrow . Patients must prior radiotherapy index lesion unless clearly progressive disease site measurable disease outside area prior radiation . Clinically significant laboratory abnormality CNS metastases Any malignancy within 5 year immediately prior first dose study medication exception basal cell nonmetastatic squamous cell carcinoma skin , carcinoma insitu cervix The need chronic ( i.e. , &gt; 7 day ) oral intravenous corticosteroid therapy Any comorbidity condition , opinion investigator , may interfere assessment procedure protocol Patients within 30 day chemotherapy , radiation therapy , immunotherapy , investigational medication melanoma . Patients must recover side effect treatment order enrol . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>